Action Centessa Pharmaceuticals - 0ACX

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

8 096

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

Clôture Veille

0,00

Ouverture

Dernière Transaction

15.6443

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

0,00

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

6,85M

Bénéfice net

-151,09M

Secteur

Coml Physical, Biologcl Resh

Industrie

Coml Physical, Biologcl Resh

Site Web

www.centessa.com

Siège social

Cheshire, Gbr

Fondé

Centessa Pharmaceuticals Plc est coté dans le secteur Coml Physical, Biologcl Resh de la London Stock Exchange avec le ticker 0ACX. Le dernier cours de clôture d'Centessa Pharmaceuticals était de US$0,00. Au cours de la dernière année, les actions de Centessa Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Centessa Pharmaceuticals compte actuellement 0 actions en circulation.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACX - Frequently Asked Questions (FAQ)

What is the current Centessa Pharmaceuticals share price?

The current share price of Centessa Pharmaceuticals is US$ 0,00

What is the 1 year trading range for Centessa Pharmaceuticals share price?

Centessa Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Centessa Pharmaceuticals?

Centessa Pharmaceuticals reports financial results in USD

What is the latest annual turnover for Centessa Pharmaceuticals?

The latest annual turnover of Centessa Pharmaceuticals is USD 6,85M

What is the latest annual profit for Centessa Pharmaceuticals?

The latest annual profit of Centessa Pharmaceuticals is USD -151,09M

What is the registered address of Centessa Pharmaceuticals?

The registered address for Centessa Pharmaceuticals is 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE, WA14 2DT

What is the Centessa Pharmaceuticals website address?

The website address for Centessa Pharmaceuticals is www.centessa.com

Which industry sector does Centessa Pharmaceuticals operate in?

Centessa Pharmaceuticals operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ADMEAdm Energy Plc	0,35p (59,09%)	9,76M
WSGWestminster Group Plc	1,40p (27,27%)	3,23M
EUAEurasia Mining Plc	6,20p (22,77%)	33,44M
WHRWarehouse Reit Plc	98,90p (16,63%)	13,38M
MET1Metals One Plc	0,575p (15,00%)	3,65M
BUCBuilt Cybernetics Plc	1,60p (-81,18%)	520k
SAVESavannah Energy Plc	9,65p (-63,24%)	238,56M
TIGTeam Internet Group Plc	54,30p (-44,93%)	5,38M
VELAVela Technologies Plc	0,0029p (-42,00%)	1,51B
ALBAAlba Mineral Resources	0,0135p (-27,03%)	152,03M
VELAVela Technologies Plc	0,0029p (-42,00%)	1,51B
TRPTower Resources Plc	0,023p (-2,13%)	336,13M
CORCorpus Resources Plc	0,0145p (3,57%)	267,93M
SAVESavannah Energy Plc	9,65p (-63,24%)	238,56M
GWMOGreat Western Mining Corporation Plc	0,01p (11,11%)	234,69M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Centessa Pharmaceuticals Plc (0ACX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Centessa Pharmaceuticals Plc

0ACX Dernières nouvelles

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Centessa Pharmaceuticals Plc (0ACX) Cours

Centessa Pharmaceuticals Plc (0ACX)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Centessa Pharmaceuticals Plc

0ACX Dernières nouvelles

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE